Oric Pharmaceuticals
Ajit Narang has a diverse work experience spanning several organizations. Ajit currently holds the position of VP, Head of CMC at ORIC Pharmaceuticals Inc. since September 2021. Prior to this, they worked at Genentech from 2016 to 2021, serving as Sr. Principal Scientist, Principal Scientist, and Sr. Scientist during different periods. Before joining Genentech, they worked as a Principal Scientist at Bristol-Myers Squibb from 2007 to 2016. Ajit also gained experience at Wockhardt USA as a Sr Research Investigator from 2006 to 2007. Ajit started their career as a Research Scientist at Ranbaxy in 1998, before pursuing graduate studies at the University of Tennessee from 2001 to 2006.
Ajit Narang completed their Bachelor of Pharmacy degree in Pharmaceutical Sciences from Delhi University, graduating in 1996. Ajit then pursued their Master of Pharmacy degree in Pharmaceutics from Banaras Hindu University, graduating in 1998. Following that, they attended The University of Tennessee Health Science Center and obtained their Ph.D. in Pharmaceutics in 2006.
This person is not in any teams
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.